Diffuse large B-cell lymphoma with TEL/ETV6 translocation

Human Pathology

Volumn 40, Issue 4, 2009, Pages 588-593

  Sevilla, Deborah W ^a   Nandula, Subhadra V ^a   Colovai, Adriana I ^a   Alexander, Suzy ^a   Murty, Vundavalli V ^a   Alobeid, Bachir ^a   Bhagat, Govind ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Cytogenetics; Diffuse Large B Cell Lymphoma; Karyotype; TEL, ETV6; Translocation

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IFOSFAMIDE; NAVELBINE; PREDNISONE; PROCARBAZINE; PROTEIN BCL 6; RITUXIMAB; TRANSCRIPTION FACTOR ETV6; VINBLASTINE; VINCRISTINE;

ADULT; ALLELE; ALTERNATIVE BREAKPOINT REGION; ARTICLE; B CELL LYMPHOMA; BLOOD DISEASE; CASE REPORT; CELL STRUCTURE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE LOSS; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; IMMUNOCYTOCHEMISTRY; KARYOTYPE; LARGE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; PHENOTYPIC VARIATION; STEM CELL TRANSPLANTATION;

ADULT; CHROMOSOME ABERRATIONS; FEMALE; FLOW CYTOMETRY; GENE REARRANGEMENT, B-LYMPHOCYTE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEOPLASMS, SECOND PRIMARY; PROTO-ONCOGENE PROTEINS C-ETS; REPRESSOR PROTEINS; TRANSLOCATION, GENETIC;

EID: 62049086088     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.08.012     Document Type: Article

References (20)

1. Bohlander S.K. ETV6: a versatile player in leukemogenesis. Semin Cancer Biol 15 (2005) 162-174
2. Mitelman F. Catalog of chromosome aberrations in cancer (1991), Liss, New York
3. Hoglund M., Johansson B., Pedersen-Bjergaard J., et al. Molecular characterization of 12p abnormalities in hematologic malignancies: deletion of KIP1, rearrangement of TEL, and amplification of CCND2. Blood 87 (1996) 324-330
4. Takeuchi S., de Vos S., Takeuchi N., et al. Allelic loss during progression of follicular lymphoma. Leuk Res 28 (2004) 567-569
5. Pasqualucci L., Compagno M., Houldsworth J., et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 203 (2006) 311-317
6. Kobayashi H., Montgomery K.T., Bohlander S.K., et al. Fluorescence in situ hybridization mapping of translocations and deletions involving the short arm of human chromosome 12 in malignant hematologic diseases. Blood 84 (1994) 3473-3482
7. Sato Y., Suto Y., Pietenpol J., et al. TEL and KIP1 define the smallest region of deletions on 12p13 in hematopoietic malignancies. Blood 86 (1995) 1525-1533
8. Wlodarska I., La Starza R., Baens M., et al. Fluorescence in situ hybridization characterization of new translocations involving TEL (ETV6) in a wide spectrum of hematologic malignancies. Blood 91 (1998) 1399-1406
9. Grimshaw S.J., Mott H.R., Stott K.M., et al. Structure of the sterile alpha motif (SAM) domain of the Saccharomyces cerevisiae mitogen-activated protein kinase pathway-modulating protein STE50 and analysis of its interaction with the STE11 SAM. J Biol Chem 279 (2004) 2192-2201
10. Schwaller J., Frantsve J., Aster J., et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo-and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. Embo J 17 (1998) 5321-5333
11. Zelent A., Greaves M., and Enver T. Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene 23 (2004) 4275-4283
12. Kuno Y., Abe A., Emi N., et al. Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12). Blood 97 (2001) 1050-1055
13. Speck N.A., and Gilliland D.G. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2 (2002) 502-513
14. Chiarle R., Budel L.M., Skolnik J., et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 95 (2000) 619-626
15. Lloyd R.V., Erickson L.A., Jin L., et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154 (1999) 313-323
16. Quintanilla-Martinez L., Davies-Hill T., Fend F., et al. Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. Blood 101 (2003) 3181-3187
17. Gesk S., Klapper W., Martin-Subero J.I., et al. A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. Blood 108 (2006) 1109-1110
18. Herens C., Lambert F., Quintanilla-Martinez L., et al. Cyclin D1-negative mantle cell lymphoma with cryptic t(12;14)(p13;q32) and cyclin D2 overexpression. Blood 111 (2008) 1745-1746
19. Qian L., Gong J., Liu J., et al. Cyclin D2 promoter disrupted by t(12;22)(p13;q11.2) during transformation of chronic lymphocytic leukaemia to non-Hodgkin's lymphoma. Br J Haematol 106 (1999) 477-485
20. Butler M.P., Iida S., Capello D., et al. Alternative translocation breakpoint cluster region 5′ to BCL-6 in B-cell non-Hodgkin's lymphoma. Cancer Res 62 (2002) 4089-4094